Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial
In: Journal of Clinical Oncology, Jg. 34 (2016-05-20), S. 556-556
Online
unknown
Zugriff:
556Background: The 21-gene Recurrence Score (RS) assay, nodal status, grade, and ER, PR, Ki67, or IHC4 are recommended for chemotherapy (CT) decision making in HR+/HER2- EBC. The phase III PlanB tr...
Titel: |
Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial
|
---|---|
Autor/in / Beteiligte Person: | Aktas, Bahriye ; Nuding, Benno ; Kümmel, Sherko ; Kates, Ronald E. ; Stefek, Andrea ; Svedman, Christer ; Nitz, Ulrike ; Kraemer, Stefan ; Reimer, Toralf ; Kreipe, Hans ; Krabisch, Petra ; Wuerstlein, Rachel ; Clemens, Michael J. ; Liedtke, Cornelia ; Christgen, Matthias ; Shak, Steven ; Lorenz-Salehi, F ; Gluz, Oleg ; Harbeck, Nadia ; Just, Marianne |
Link: | |
Zeitschrift: | Journal of Clinical Oncology, Jg. 34 (2016-05-20), S. 556-556 |
Veröffentlichung: | American Society of Clinical Oncology (ASCO), 2016 |
Medientyp: | unknown |
ISSN: | 1527-7755 (print) ; 0732-183X (print) |
DOI: | 10.1200/jco.2016.34.15_suppl.556 |
Schlagwort: |
|
Sonstiges: |
|